PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 2004 May; 48(5): 1797–1802.
PMCID: PMC400543

Clinical Strains of Pseudomonas aeruginosa Overproducing MexAB-OprM and MexXY Efflux Pumps Simultaneously

Abstract

Simultaneous overexpression of the MexAB-OprM and MexXY efflux systems was demonstrated by real-time reverse transcription-PCR and immunoblotting experiments for 12 multiresistant clinical isolates of Pseudomonas aeruginosa. DNA sequencing analysis showed that nine of these strains (named agrZ mutants) harbored mutations in mexZ, the product of which downregulates the expression of the mexXY operon. In addition, 8 of the 12 strains exhibited mutations in genes known to control transcription of the mexAB-oprM operon. Four of them were nalB mutants with alterations in the repressor gene mexR, three of them appeared to be nalC mutants deficient in gene PA3721 and overexpressing gene PA3720, and one strain was a nalB nalC double mutant. For MexAB-OprM as well as for MexXY, no clear correlation could be established between (i) the types of mutations, (ii) the expression level of mexA or mexX, and (iii) resistance to effluxed antibiotics. Finally, three isolates, named agrW mutants, overproduced MexXY and had an intact mexZ gene, and four strains overproduced MexAB-OprM and had intact mexR and PA3721 genes (nalD mutants). These data show that clinical isolates are able to broaden their drug resistance profiles by coexpressing two Mex efflux pumps and suggest the existence of additional regulators for MexAB-OprM and MexXY.

Polyspecific efflux pumps are essential mechanisms in the defense of Pseudomonas aeruginosa against antibiotics, antiseptics, and inhibitors. To date, six of these systems belonging to the RND (resistance nodulation/cell division) family of transporters have been characterized in the pathogen, MexAB-OprM (31), MexCD-OprJ (30), MexEF-OprN (13), MexXY (23, 34), MexJK (3), and MexGHI-OpmD (1). With their partially overlapping substrate specificities, MexAB-OprM and MexXY play a key role in the natural resistance of P. aeruginosa to antibiotics. Constitutively expressed in wild-type bacteria, the tripartite system MexAB-OprM confers basal resistance to a wide range of drugs, including β-lactams (except imipenem), fluoroquinolones, tetracyclines, macrolides, chloramphenicol, novobiocin, trimethoprim, and sulfamethoxazole (12, 16, 26, 38). On the other hand, the MexXY proteins, which are produced solely in response to some agents, allow P. aeruginosa to adapt rapidly to inhibitory concentrations of aminoglycosides, tetracyclines, and macrolides (7, 20). Several candidate proteins such as OprM (23, 34), OpmB (24), and OmpG and OmpI (11) have been proposed to interact with MexXY in reference strain PAO1 to form a functional tripartite efflux machinery.

Overproduction of MexAB-OprM may lead to significant multidrug resistance in clinical isolates of P. aeruginosa (39). In nalB mutants, upregulation of the mexAB-oprM operon results from various alterations in the adjacent repressor gene mexR (32, 35, 36, 39). Other mutants, named nalC, harbor intact mexR genes (36, 39). Recently, Cao et al. (L. Cao, R. Srikumar, and K. Poole, Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., abstr. 430, 2002) reported that nalC mutants derived from PAO1 carried mutations in gene PA3721. The product of PA3721 appears to repress a two-gene operon (PA3720 and PA3719) of unknown function whose overexpression in nalC mutants may be responsible for MexAB-OprM overproduction.

As for MexAB-OprM, the MexXY proteins may be overproduced constitutively as a result of mutations occurring inside or outside the putative repressor gene named mexZ (formerly amrR), adjacent to and divergently transcribed from the mexXY operon (34, 36a, 37). Mutants of PAO1 are usually two- to eightfold more resistant to aminoglycosides and fluoroquinolones than their wild-type parents (19, 20, 37). However, in vitro screening for spontaneous mutants able to withstand higher concentrations of aminoglycosides often leads to the selection of bacteria with multiple defects in addition to MexXY-mediated efflux (19, 37). The contribution of MexXY to the resistance of clinical isolates such as those recovered from cystic fibrosis patients remains to be explored (37).

While data are accumulating on the occurrence of MexAB-OprM- and MexXY-overproducing strains in the clinical setting (6, 15, 28, 37, 39), little is known about the possible implication of these two systems in the emergence of isolates with reduced susceptibilities to β-lactams, aminoglycosides, and fluoroquinolones, three major classes of antibiotics used for the treatment of P. aeruginosa infections. Coexpression of MexCD-OprJ and MexEF-OprN has been described sporadically for fluoroquinolone-resistant cystic fibrosis isolates (8), and one multidrug-resistant strain deficient in the major porin OprF was found to overproduce both MexAB-OprM and MexEF-OprN (33). According to recent observations (14), simultaneous expression of two or three Mex pumps (MexAB-OprM, MexCD-OprJ, and MexEF-OprN) is expected to have additive effects on the MICs of common effluxed substrates compared with single-efflux mutants.

In this work, we demonstrate that concomitant overexpression of MexAB and OprM occurs in clinical strains of P. aeruginosa and that these two systems may superimpose their drug efflux capabilities, thus contributing to the emergence of multidrug resistance. We also show that overexpression of the two efflux systems may result from mutations affecting multiple regulatory genes.

MATERIALS AND METHODS

Bacterial strains, media, and growth conditions.

Twelve clinical isolates of Pseudomonas aeruginosa isolated between 1997 and 2000 in the university-affiliated Hospital of Besançon (eastern France) were selected because of their nonenzymatic resistance to both β-lactams and aminoglycosides. These strains, which belonged to serotypes O:1, O:4, O:11, and O:14, were found to be genotypically distinct by random amplified polymorphic DNA analysis (18). They were isolated from urine (WL22, WL24, 1217, 1237, 1562, and 2172), tracheal aspirates (1113, 1727, and 1738), blood catheters (1250 and 2151), or surgical wounds (2085). Bacteria were cultured at 37°C in either Luria-Bertani broth (LB), Mueller-Hinton broth with adjusted concentrations of Ca2+ and Mg2+ (MHB; BBL, Cockeysville, Md.), or Mueller-Hinton agar plates (MHA; Bio-Rad, Ivry-sur-Seine, France). The wild-type P. aeruginosa strain PAO1 (K. Stover) was used as the susceptible reference strain throughout the study, and its MexAB-OprM-overproducing nalB mutant strain PT629 (a gift from Thilo Köhler, Gevena, Switzerland) served as a control in gene expression experiments.

Mutants constitutively overproducing MexXY were obtained by incubating strain PAO1 for 2 h in MHB containing 2 μg of gentamicin per ml (1× MIC) and then plating the bacteria on selective MHA plates supplemented with 2 μg of cefepime per ml (1× MIC). Western blot and nucleotide sequencing experiments showed that one resistant clone (named Mut-Gr1) overproduced MexY as a result of a single mutation (C307→T) that introduced a stop codon in the coding sequence of the repressor gene mexZ (36a). A mutant overproducing both MexAB-OprM and MexXY was obtained by plating an exponential-phase culture of Mut-Gr1 on selective MHA plates supplemented with 10 μg of aztreonam per ml. Reverse transcription-PCR and nucleotide sequencing showed that this double mutant, named ATM4, overproduced MexA as a result of a single-amino-acid substitution (Ala61→Pro) in the repressor MexR.

Bacterial resistance to antibiotics.

Clinical strains of P. aeruginosa potentially overexpressing the two systems MexAB-OprM and MexXY were retrospectively selected from our laboratory collection on the basis of their drug susceptibility profiles. Typically, MexAB-OprM overproducers exhibit reduced susceptibilities to most β-lactams except imipenem, with MICs of aztreonam at least fourfold higher than that of ceftazidime (39). On the other hand, MexXY-overexpressing mutants show decreased susceptibilities to gentamicin, tobramycin, amikacin, isepamycin, and cefepime, with MICs at least twofold higher than that for wild-type susceptible strains (unpublished observation). None of these isolates displayed typical resistance profiles involving MexCD-OprJ (resistance to cefpirome and hypersusceptibility to both ticarcillin and aminoglycosides) or MexEF-OprN (resistance to imipenem and hypersusceptibility to both ticarcillin and aminoglycosides).

Susceptibility testing was performed by the standard microdilution method in MHB with bacterial inocula of about 2.5 × 105 CFU per ml (2). Some of the antibiotics tested were kindly provided by Eli Lilly (tobramycin), Bristol-Meyers Squibb (amikacin, aztreonam, and cefepime), and Glaxo SmithKline (ticarcillin and ceftazidime). Isoelectrofocusing experiments with crude bacterial lysates (6, 22) allowed the selection of 12 strains showing no detectable β-lactamase activity except for faint, wild-type expression of the chromosomally encoded enzyme AmpC (data not shown). The mechanisms of resistance to aminoglycosides in these isolates were deduced from the levels of susceptibility to kanamycin, tobramycin, gentamicin, amikacin, isepamicin, netilmicin, neomycin, 5-epinetilmicin, 2′-netilmicin, 6′-netilmicin, apramycin, and fortimicin, as determined with the aminoglycoside resistance test kit provided by the Schering Plough Research Institute. Apramycin and fortimicin were obtained as titrated powders from Helm (Hamburg, Germany) and Kyowa Hakko Kogyo (Tokyo, Japan), respectively.

Immunodetection of MexY and OprM.

Bacterial membranes were isolated and analyzed by Western blotting with MexY- and OprM-specific antisera as previously described (7).

PCR conditions and DNA sequencing.

Chromosomal DNA was extracted with the EZNA bacterial DNA kit (Omega, Doraville, Ga.). The coding sequences of mexR and mexZ as well as the intergenic regions between mexA and mexR (mexA-mexR) and between mexX and mexZ (mexX-mexZ) were amplified and sequenced as previously described (6). PCR amplification of the putative repressor nalC (PA3721) was performed with primers nalC1 and nalC2 (Table (Table1)1) in a DNA thermal cycler (Perkin-Elmer, Norwalk, Conn.) for 30 cycles, each cycle consisting of 40 s at 94°C for denaturation, 1 min at 69°C for annealing, and 1 min at 72°C for polymerization. PCR amplicons were sequenced on both strands.

TABLE 1.
Primers used for DNA amplification

Quantitative real-time reverse transcriptase-PCR.

Total RNA were isolated from exponential-phase cultures (A600 = 1) with the Qiagen RNeasy protocol (Qiagen, Courtaboeuf, France). The RNA samples were further treated with DNase (RQ1 DNase; Promega, Madison, Wis.) and purified by phenol-chloroform extraction and ethanol precipitation (J.-L. Dumas, C. Van Delden, and T. Köhler, submitted for publication). We reverse transcribed 2 μg of total RNA with ImPromII reverse transcriptase (Promega) according to the supplier's instructions. The mexA and mexX cDNAs were subsequently quantified in a Rotor Gene RG3000 RealTime PCR machine (Corbett Research, Sydney, Australia) with a SybrGreen Quantitect kit (Qiagen) with primers (Dumas et al., submitted for publication) mexA-1/mexA-2 for mexA and mexX-1 for mexX (Table (Table1).1). The expression levels of PA3720 (putative gene nalC) were estimated after amplification with primers PA3720-1 and PA3720-2 (Table (Table1).1). To correct for differences in the amount of starting materials, the ribosomal rpsL gene was chosen as a reference housekeeping gene (primers rpsL-1 and rpsL-2; Table Table1).1). The results are presented as ratios of gene expression between the target gene (mexA, mexX, or nalC) and the reference gene (rpsL) (29).

RESULTS AND DISCUSSION

Selection of double-efflux clinical strains of P. aeruginosa.

Twelve genotypically distinct strains were selected for their resistance profiles to both β-lactams and aminoglycosides, evoking concomitant overproductions of efflux systems MexAB-OprM and MexXY (see Materials and Methods). None of these isolates were derepressed for the chromosomally encoded AmpC β-lactamase or produced transmissible secondary β-lactamases.

As indicated in Table Table2,2, these strains were two- to eightfold more resistant to ticarcillin, aztreonam, and cefepime than was the wild-type reference strain PAO1. All of them remained susceptible to ceftazidime according to the standard breakpoints (MICs, ≤8 μg/ml). The 12 strains also displayed reduced susceptibilities to all 12 aminoglycosides tested (Schering Plough kit), including the enzyme-recalcitrant compounds apramycin and fortimicin (Table (Table2).2). This decreased susceptibility strongly suggested the expression of one or several nonenzymatic resistance mechanisms to aminoglycosides in the selected bacteria. Except for the well-known chromosomally encoded APH(3′)-II enzyme, which naturally provides P. aeruginosa with high resistance to kanamycin and neomycin (27), no additional enzymatic mechanisms could be detected in six strains (1113, 1250, 1727, 1738, 2151, and 2172), while the aminoglycoside-modifying enzymes ANT(2")-I, AAC(6′)-II, and AAC(3)-VI were phenotypically identified in isolates WL24, 1237, and 2085, respectively. Finally, three isolates (WL22, 1217, and 1562) showed complex susceptibility profiles, suggesting the synthesis of several modifying enzymes. The resistance of the 12 strains to ciprofloxacin varied greatly, with MICs ranging from 0.5 to 64 μg/ml (Table (Table22).

TABLE 2.
Susceptibilities of P. aeruginosa strains to antimicrobial agents

Overexpression of mexA and mexX.

Upregulation of the MexAB-OprM and MexXY efflux systems in the P. aeruginosa strains was assessed by determining the transcription levels of mexA and mexX by quantitative real-time reverse transcription-PCR (Table (Table3).3). Confirming that the selected isolates are double efflux mutants, mexA and mexX appeared to be expressed 2.6- to 34.8-fold and 22- to 312-fold, respectively, more than in PAO1. Control experiments performed in parallel showed that the transcription levels of mexA and mexX in eight randomly chosen, susceptible clinical strains were very similar to that of the reference strain (0.8- ± 0.2-fold and 1- ± 0.3-fold that of PAO1, respectively). These results were in agreement with membrane immunoblots showing increased amounts of MexY and OprM proteins in the mutants (data not shown).

TABLE 3.
Genetic analysis of MexAB-OprM- and MexXY-overproducing strains of P. aeruginosa

Mutations in repressor gene mexZ.

To gain insight into the mutational events responsible for MexXY upregulation in the 12 double-efflux strains, we amplified and sequenced the intergenic region between mexX and mexZ as well as mexZ, the repressor gene of the mexXY operon (C. Vogne, D. Hocquet, J. Ramos Aires, F. El Garch, P. Plésiat, Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., abstr. C1-434, 2002). Compared with the genome sequence of PAO1 (available at www.pseudomonas.com), nine isolates were found to harbor mutations, resulting in (i) single-amino-acid substitutions in MexZ (strains WL22, 1562, 2085, 2151, and 2172) or (ii) production of aberrant peptides (strains 1113, 1217, 1237, and 1250) (Table (Table3).3). Most of these mutations (seven of nine) occurred in the helix-turn-helix N-terminal motif of MexZ (between positions 32 and 53), a domain predicted by the EMBOSS algorithm (available at www.pasteur.fr) to be involved in DNA binding. Two strains (1738 and 2085) exhibited single mutations in the mexX-mexZ intergenic region outside the putative promoter sequences of mexZ and mexXY (data not shown). Finally, strains WL24 and 1727 had nucleotide sequences identical to that of PAO1. No correlation could be established between the various MexZ alterations, the expression level of mexX, which varied from 29.6- to 312-fold that of PAO1 (Table (Table3),3), and resistance to aminoglycosides (Table (Table2).2). Important variations in mexX transcription (22- to 300-fold higher than that in PAO1) were also observed in the three strains harboring intact mexZ genes (WL24, 1738, and 1727).

In contrast to previous observations made on cystic fibrosis isolates of P. aeruginosa (37), stable derepression of mexXY in the double-efflux mutants described here was mostly associated with alterations in mexZ. We thus propose the names agrZ (for aminoglycoside resistance dependent on mexZ) and agrW (unknown locus) for the genotypes of MexXY-overproducing mutants with altered and intact mexZ genes, respectively. In the absence of specific aminoglycoside-modifying enzymes, overexpression of mexXY in both types of mutants as well as in the mexZ-null mutant Mut-Gr1 was associated with low to moderate resistance to all the aminoglycosides tested (MICs increased two- to eightfold) compared to PAO1. Although relevant in some clinical situations where aminoglycosides diffuse poorly at the site of infection (4), these resistance levels are far below that conferred by aminoglycoside-modifying enzymes for major therapeutic agents such as amikacin (e.g., isolates WL22 and 1562) and tobramycin (e.g., WL22 and 1237) (Table (Table2).2). The contribution of the MexXY-OprM efflux system to the overall resistance of strains producing aminoglycoside-modifying enzymes remains to be explored.

Mutations in the mexABoprM operon regulatory genes.

Sequencing experiments revealed several other mutations in the double-efflux strains (Table (Table3).3). One strain (1250) harbored an A→G substitution of unknown significance in the mexA-mexR intergenic region at position −5 (position 1 being the A of the mexR start codon), which is distant from the MexR binding sites (5). MexR amino acid sequences strictly identical to that published by Poole et al. (32) were found in six putative nalC strains (WL24, 1217, 1250, 1562, 1738, and 2172). Five other strains (WL22, 1113, 1237, 2085, and 2151) harbored a Val126→Glu substitution in MexR, already observed in susceptible wild-type isolates and considered nonsignificant (28, 39). In this group, four nalB mutants (WL22, 1237, 2085, and 2151) displayed an already known mutation in mexR that results in a Lys44→Met substitution (9), affecting the DNA binding domain of MexR (from residues 37 to 97) (17). Finally, a frameshift mutation (7-bp insertion between nucleotides 355 and 361) was discovered in the mexR sequence of another nalB strain, 1727. Similar genetic events leading to frameshifts in mexR have already been reported in MexAB-OprM-overexpressing mutants (36, 39).

In order to further characterize the mutants harboring intact mexR genes, we sequenced PA3721, the repressor gene of the MexAB-OprM putative activator PA3720-PA3719 (Cao et al., abstr. 430) and assessed the expression of PA3720 by real-time reverse transcription-PCR (Table (Table3).3). Compared with PAO1, three recurrent substitutions in repressor protein PA3721 were noticed in 11 of 12 isolates: Gly71→Glu, Glu153→Gln, and Ser209→Arg. These amino acid differences with PAO1 do not seem to have an impact on PA3721 activity, as they were also present in four of four susceptible wild-type environmental strains of P. aeruginosa (data not shown). In addition, strain 1237, which overexpressed PA3720 only 3.7-fold more than PAO1, appeared to have a Ser46→Ala substitution in the PA3721 repressor. More importantly, three isolates were found to strongly overexpress PA3720 (147- to 224-fold more than in PAO1), suggesting that they are nalC mutants. Two of them harbored single-amino-acid substitutions in PA3721: Met151→Thr for isolate 2172, and Leu61→Pro for isolate 1738. The third strain (1250) displayed a large 500-bp deletion in PA3721. Another strain (1727) already characterized as a nalB mutant (see above) and showing moderate overexpression of PA3720 (9.9-fold more than in PAO1) appeared to carry an Asp76→Glu substitution in PA3721. Finally, various differences in the DNA sequences upstream and downstream of the PA3721 gene were observed between five isolates with low levels of PA3720 expression (WL22, 1113, 1237, 2085, and 2151) and PAO1 (Table (Table3).3). The effect of these nucleotide changes on PA3720 transcription is unclear.

As for MexXY, the transcription levels of mexA in the isolates were not clearly correlated with particular types of mutations in mexR or PA3721. The MICs of β-lactams such as ticarcillin and aztreonam, which are known to be good substrates for MexAB-OprM (21), also did not vary with the degree of mexA overexpression (Table (Table2).2). This observation is not surprising by itself, as multiple factors are involved in determining the susceptibility of a given isolate to antibiotics (e.g., outer membrane permeability, affinity of drug targets, degree of inducibility of AmpC enzyme, etc.) (25). In contrast to previous results obtained with reference strain PAO1 (36), the clinical nalC mutant isolates reported here and elsewhere (39) did not appear to be less resistant than the nalB mutants to β-lactams.

In addition to well known nalB strains (32, 36, 39), this work identified three nalC mutants and one nalB nalC mutant among the 12 MexAB-OprM/MexXY-overproducing strains selected. This indicates that nalC mutants with alterations in PA3721, like those initially characterized in vitro from PAO1 (Cao et al., abstr. 430), are rather prevalent among resistant clinical isolates. As indicated in Table Table3,3, mutations in both mexR and PA3721 could have additive effects on mexA expression, as nalB nalC isolate 1727 displayed the highest mexA transcription levels (about twofold higher than that of nalB or nalC mutants). A similar observation has been made for a ΔacrR Δmar double mutant of Escherichia coli which expressed greater amounts of acrB mRNA than single mar mutants (10). Interestingly, interplay between mexR and nalC has already been suspected in PAO1 (36). Finally, no less than four P. aeruginosa strains (WL24, 1113, 1217, and 1562), which we propose to call nalD type mutants, appeared to contain no mutation in the known regulatory genes for MexAB and OprM.

Lee et al. reported that concomitant overproduction of two Mex pumps in PAO1 produces additive effects on the resistance to shared antibiotic substrates (14). This tends to suggest that clinical strains of P. aeruginosa may increase their resistance to a given compound by coexpressing two Mex efflux systems. In support of this, the clinical double-efflux mutants studied here appeared to be more resistant to cefepime (Table (Table2)2) than mutants overproducing MexAB-OprM (PT629) or MexXY (Mut-Gr1) alone (MIC, 8 to 16 versus 4 μg/ml). Convincing evidence of cooperation between MexXY and MexAB-OprM for the extrusion of common substrates is also provided by the double mutant ATM4, which was two- to fourfold more resistant to cefepime and ciprofloxacin than the single mutants Mut-Gr1 and PT629, respectively (Table (Table2).2). Besides this, our results show that superimposition of the resistance profiles conferred by two efflux systems, such as MexAB-OprM (β-lactams) and MexXY (aminoglycosides), may be an efficient way for infectious strains to become less susceptible to numerous antibiotics. In a therapeutic perspective, efflux inhibitors of broad specificity would be potentially interesting to reverse the resistance or prevent the emergence of such double-efflux mutants.

Acknowledgments

We thank Christiane Bailly and Ingrid André for invaluable technical assistance.

C.V. was sponsored by the French Cystic Fibrosis Association “Vaincre la mucoviscidose.”

REFERENCES

1. Aendekerk, S., B. Ghysels, P. Cornelis, and C. Baysse. 2002. Characterization of a new efflux pump, MexGHI-OpmD, from Pseudomonas aeruginosa that confers resistance to vanadium. Microbiology 148:2371-2381. [PubMed]
2. Balows, A., W. J. Hausler, Jr., K. L. Herrmann, H. D. Isenberg, and H. J. Shadomy. 1991. Manual of clinical microbiology, 5th ed. ASM Press, Washington, D.C.
3. Chuanchuen, R., C. T. Narasaki, and H. P. Schweizer. 2002. The MexJK efflux pump of Pseudomonas aeruginosa requires OprM for antibiotic efflux but not for efflux of triclosan. J. Bacteriol. 184:5036-5044. [PMC free article] [PubMed]
4. Craig, W. A., and S. C. Ebert. 1994. Antimicrobial therapy in Pseudomonas aeruginosa infections, p. 441-517. In A. L. Baltch and R. P. Smith (ed.), Pseudomonas aeruginosainfections and treatment. Marcel Dekker, Inc., New York, N.Y.
5. Evans, K., L. Adewoye, and K. Poole. 2001. MexR repressor of the mexAB-oprM multidrug efflux operon of Pseudomonas aeruginosa: identification of MexR binding sites in the mexA-mexR intergenic region. J. Bacteriol. 183:807-812. [PMC free article] [PubMed]
6. Hocquet, D., X. Bertrand, T. Kohler, D. Talon, and P. Plesiat. 2003. Genetic and phenotypic variations of a resistant Pseudomonas aeruginosa epidemic clone. Antimicrob. Agents Chemother. 47:1887-1894. [PMC free article] [PubMed]
7. Hocquet, D., C. Vogne, F. El Garch, A. Vejux, N. Gotoh, A. Lee, O. Lomovskaya, and P. Plesiat. 2003. MexXY-OprM efflux pump is necessary for adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob. Agents Chemother. 47:1371-1375. [PMC free article] [PubMed]
8. Jalal, S., O. Ciofu, N. Hoiby, N. Gotoh, and B. Wretlind. 2000. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 44:710-712. [PMC free article] [PubMed]
9. Jalal, S., and B. Wretlind. 1998. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb. Drug Resist. 4:257-261. [PubMed]
10. Jellen-Ritter, A. S., and W. V. Kern. 2001. Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants selected with a fluoroquinolone. Antimicrob. Agents Chemother. 45:1467-1472. [PMC free article] [PubMed]
11. Jo, J. T., F. S. Brinkman, and R. E. Hancock. 2003. Aminoglycoside efflux in Pseudomonas aeruginosa: involvement of novel outer membrane proteins. Antimicrob. Agents Chemother. 47:1101-1111. [PMC free article] [PubMed]
12. Köhler, T., M. Kok, M. Michéa-Hamzehpour, P. Plésiat, N. Gotoh, T. Nishino, L. K. Curty, and J. C. Pechère. 1996. Multidrug efflux in intrinsic resistance to trimethoprim and sulfamethoxazole in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40:2288-2290. [PMC free article] [PubMed]
13. Köhler, T., M. Michéa Hamzehpour, U. Henze, N. Gotoh, L. Kocjancic Curty, and J.-C. Pechère. 1997. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol. Microbiol. 23:345-354. [PubMed]
14. Lee, A., W. Mao, M. S. Warren, A. Mistry, K. Hoshino, R. Okumura, H. Ishida, and O. Lomovskaya. 2000. Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J. Bacteriol. 182:3142-3150. [PMC free article] [PubMed]
15. Li, X. Z., D. M. Livermore, and H. Nikaido. 1994. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob. Agents Chemother. 38:1732-1741. [PMC free article] [PubMed]
16. Li, X. Z., H. Nikaido, and K. Poole. 1995. Role of MexA-MexB-OprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1948-1953. [PMC free article] [PubMed]
17. Lim, D., K. Poole, and N. C. Strynadka. 2002. Crystal structure of the MexR repressor of the mexRAB-oprM multidrug efflux operon of Pseudomonas aeruginosa. J. Biol. Chem. 277:29253-29259. [PubMed]
18. Mahenthiralingam, E., M. E. Campbell, J. Foster, J. S. Lam, and D. P. Speert. 1996. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J. Clin. Microbiol. 34:1129-1135. [PMC free article] [PubMed]
19. Mao, W., M. S. Warren, A. Lee, A. Mistry, and O. Lomovskaya. 2001. MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 45:2001-2007. [PMC free article] [PubMed]
20. Masuda, N., E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino. 2000. Contribution of the MexX-MexY-OprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:2242-2246. [PMC free article] [PubMed]
21. Masuda, N., E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino. 2000. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:3322-3327. [PMC free article] [PubMed]
22. Mathew, A., A. M. Harris, M. J. Marshall, and G. W. Ross. 1975. The use of analytical isoelectric focusing for detection and identification of beta-lactamases. J. Gen. Microbiol. 88:169-178. [PubMed]
23. Mine, T., Y. Morita, A. Kataoka, T. Mizushima, and T. Tsuchiya. 1999. Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:415-417. [PMC free article] [PubMed]
24. Murata, T., N. Gotoh, and T. Nishino. 2002. Characterization of outer membrane efflux proteins OpmE, OpmD and OpmB of Pseudomonas aeruginosa: molecular cloning and development of specific antisera. FEMS Microbiol. Lett. 217:57-63. [PubMed]
25. Nikaido, H. 2000. Crossing the envelope: how cephalosporins reach their targets. Clin. Microbiol. Infect. 6(Suppl. 3):22-26. [PubMed]
26. Okamoto, K., N. Gotoh, and T. Nishino. 2001. Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay. Antimicrob. Agents Chemother. 45:1964-1971. [PMC free article] [PubMed]
27. Okii, M., S. Iyobe, and S. Mitsuhashi. 1983. Mapping of the gene specifying aminoglycoside 3′-phosphotransferase II on the Pseudomonas aeruginosa chromosome. J. Bacteriol. 155:643-649. [PMC free article] [PubMed]
28. Pai, H., J. Kim, J. H. Lee, K. W. Choe, and N. Gotoh. 2001. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 45:480-484. [PMC free article] [PubMed]
29. Pfaffl, M. W., G. W. Horgan, and L. Dempfle. 2002. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30:e36. [PMC free article] [PubMed]
30. Poole, K., N. Gotoh, H. Tsujimoto, Q. Zhao, A. Wada, T. Yamasaki, S. Neshat, J. Yamagishi, X. Z. Li, and T. Nishino. 1996. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol. Microbiol. 21:713-724. [PubMed]
31. Poole, K., K. Krebes, C. McNally, and S. Neshat. 1993. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J. Bacteriol. 175:7363-7372. [PMC free article] [PubMed]
32. Poole, K., K. Tetro, Q. Zhao, S. Neshat, D. E. Heinrichs, and N. Bianco. 1996. Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob. Agents Chemother. 40:2021-2028. [PMC free article] [PubMed]
33. Pumbwe, L., and L. J. Piddock. 2000. Two efflux systems expressed simultaneously in multidrug-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:2861-2864. [PMC free article] [PubMed]
34. Ramos Aires, J., T. Köhler, H. Nikaido, and P. Plésiat. 1999. Involvement of an efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob. Agents Chemother. 43:2624-2628. [PMC free article] [PubMed]
35. Saito, K., H. Yoneyama, and T. Nakae. 1999. nalB-type mutations causing the overexpression of the MexAB-OprM efflux pump are located in the mexR gene of the Pseudomonas aeruginosa chromosome. FEMS Microbiol. Lett. 179:67-72. [PubMed]
36. Srikumar, R., C. J. Paul, and K. Poole. 2000. Influence of mutations in the mexR repressor gene on expression of the MexA-MexB-OprM multidrug efflux system of Pseudomonas aeruginosa. J. Bacteriol. 182:1410-1414. [PMC free article] [PubMed]
36a. Vogne, C., J. Ramos Aires, C. Bailly, D. Hocquet, and P. Plésiat. 2004. Role of multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 48:1676-1680. [PMC free article] [PubMed]
37. Westbrock-Wadman, S., D. R. Sherman, M. J. Hickey, S. N. Coulter, Y. Q. Zhu, P. Warrener, L. Y. Nguyen, R. M. Shawar, K. R. Folger, and C. K. Stover. 1999. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob. Agents Chemother. 43:2975-2983. [PMC free article] [PubMed]
38. Zhao, Q., X. Z. Li, A. Mistry, R. Srikumar, L. Zhang, O. Lomovskaya, and K. Poole. 1998. Influence of the TonB energy-coupling protein on efflux-mediated multidrug resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 42:2225-2231. [PMC free article] [PubMed]
39. Ziha-Zarifi, I., C. Llanes, T. Köhler, J.-C. Pechère, and P. Plésiat. 1999. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob. Agents Chemother. 43:287-291. [PMC free article] [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)